NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 02 04:00PM ET
1.14
Dollar change
0.00
Percentage change
0.00
%
Index- P/E1.50 EPS (ttm)0.76 Insider Own10.53% Shs Outstand6.90M Perf Week10.68%
Market Cap7.82M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float6.14M Perf Month6.54%
Enterprise Value-8.94M PEG- EPS next Q- Inst Own10.89% Short Float0.35% Perf Quarter-11.63%
Income6.41M P/S- EPS this Y- Inst Trans-4.10% Short Ratio1.82 Perf Half Y-27.39%
Sales0.00M P/B0.20 EPS next Y- ROA35.17% Short Interest0.02M Perf YTD-27.39%
Book/sh5.83 P/C0.47 EPS next 5Y- ROE45.44% 52W High2.42 -52.95% Perf Year-41.84%
Cash/sh2.44 P/FCF- EPS past 3/5Y9.90% 20.17% ROIC15.93% 52W Low1.00 14.00% Perf 3Y-48.88%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility5.04% 5.15% Perf 5Y-96.62%
Dividend TTM- EV/Sales- EPS Y/Y TTM163.57% Oper. Margin- ATR (14)0.06 Perf 10Y-99.33%
Dividend Ex-Date- Quick Ratio14.20 Sales Y/Y TTM- Profit Margin- RSI (14)59.67 Recom-
Dividend Gr. 3/5Y- - Current Ratio14.20 EPS Q/Q32.99% SMA207.32% Beta-0.29 Target Price-
Payout- Debt/Eq0.00 Sales Q/Q- SMA504.62% Rel Volume0.72 Prev Close1.14
Employees2 LT Debt/Eq0.00 Earnings- SMA200-24.33% Avg Volume11.71K Price1.14
IPOSep 11, 2003 Option/ShortYes / Yes EPS/Sales Surpr.- - Trades Volume8,488 Change0.00%
May-21-24 09:00AM
Mar-19-24 06:53AM
Dec-18-23 11:51AM
Nov-15-23 08:30AM
07:30AM
09:15AM Loading…
Oct-31-23 09:15AM
Jun-15-23 09:15AM
May-11-23 08:30AM
Feb-02-23 09:00AM
Oct-07-22 09:00AM
Aug-15-22 08:30AM
Jul-28-22 12:49PM
09:00AM
Jul-21-22 08:30AM
Jul-19-22 08:30AM
08:30AM Loading…
Jul-11-22 08:30AM
06:00AM
Jul-05-22 03:16PM
08:30AM
Jun-23-22 09:00AM
Jun-15-22 08:30AM
Jun-13-22 08:30AM
Jun-09-22 09:00AM
Jun-08-22 08:30AM
Jun-02-22 09:00AM
May-23-22 09:00AM
May-11-22 09:00AM
Apr-27-22 09:00AM
Apr-19-22 09:00AM
Apr-13-22 09:00AM
09:00AM Loading…
Apr-05-22 09:00AM
Mar-22-22 09:00AM
Mar-16-22 09:00AM
Feb-22-22 09:00AM
Feb-14-22 09:00AM
Jan-06-22 09:00AM
Jan-04-22 09:00AM
Dec-28-21 09:00AM
Dec-15-21 09:00AM
Dec-08-21 10:16AM
Nov-30-21 01:05AM
Nov-12-21 09:00AM
Sep-27-21 09:00AM
Sep-21-21 09:00AM
Sep-16-21 09:00AM
Sep-08-21 09:00AM
Aug-31-21 09:20AM
Aug-25-21 09:00AM
Aug-23-21 04:39PM
Aug-19-21 07:19AM
Aug-16-21 09:00AM
Aug-12-21 03:00PM
Aug-09-21 05:37PM
Aug-02-21 04:58PM
Jul-14-21 08:45AM
Jul-13-21 07:57PM
Jul-09-21 07:11PM
Jul-08-21 09:00AM
Jun-24-21 09:00AM
Jun-22-21 09:00AM
Jun-18-21 09:00AM
Jun-14-21 09:00AM
Apr-01-21 09:00AM
PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Las Vegas, NV.